In this section of the page, you will find all the information you need to understand how Argenx (ARGX) dividends work. In addition, you will be able to consult the payment date, the ex-dividend date, the last day to be entitled to the payment, the money to be received per share, the yield and any other doubts that may arise.
Upcoming Argenx dividend
No change
Next payment N/A
Next payment date N/A
Last payment N/A
Last payment date N/A
00 D 00 H 00 M 00 S
Ex-Dividend: N/A
Not available

There is no upcoming dividend defined for Argenx.

There is no set last day on which buying Argenx shares generates the possibility of earning dividends.

There has been no final dividend for Argenx.

Argenx S.E., listed on the Brussels Stock Exchange, BATS EU, NASDAQ, London, Frankfurt and Vienna, using the ticker symbol ARGX, has not paid dividends to its shareholders to date.

Payout Ratio Argenx Dividends

In the last fiscal period, Argenx paid no dividends, resulting in a dividend payout ratio of 0%.
Dividend payout ratio

The dividend payout ratio, also known as the payout ratio, is an essential indicator for assessing the stability of a company's dividends. This ratio shows what proportion of the company's net profit is used to pay dividends to shareholders.

Dividend payout ratio = Total dividends ÷ Net income

Argenx has not distributed dividends in the last fiscal period, therefore, the payout ratio is 0%.
Dividend payout ratio
General recommendations

An appropriate payout ratio may vary depending on the industry, the company's growth stage and its financial health.

Payout Ratio

Dividend calendar of Argenx

There is no Dividend Calendar of Argenx defined for 2023.

Historical annual dividend yields of Argenx

Over the past 5 years, Argenx has not consistently distributed dividends.
Increasing Dividends
Increasing Dividend Program

For a company to have growing dividends by our standards, the annual dividend amount must have increased steadily for at least the last 5 years.

Dividend yield

Dividend yield of Argenx vs. the sector

Argenx's dividend yield (0.00%) is below the sector average (1.71%).
Comparison with industry average
Comparison with industry average

The company's dividend yield is compared to the industry average to determine its positioning.

Argenx's dividend yield is below the top 75% (1.71%) of the sector.
Evaluation with respect to competence.
Comparison with competitors

Imagine you have a list of dividend yields for different companies in an industry. If you look for the "top 25%% percentile", you will find a number. This number tells you that the top 25%% of the companies with the highest dividends have a yield higher than that number.

On the other hand, the "top 75%% percentile" shows you another number, which tells you that 75%% of the companies have a higher yield than that number, thus showing a more common and less high yield.

Dividend yield history in Argenx

Over the past 5 years, Argenx has not consistently distributed dividends.
Dividend stability
Dividend stability

For a company to have stable dividends by our standards, it is vital that it has not had an annual decline of more than 10% over the previous year.

Dividend history of Argenx

Argenx has never distributed dividends, so it has an empty dividend history.

Argenx dividend capture strategy

Step 1: Buy Argenx shares (ARGX) one day before ex-dividend date
Date of purchase N/A
Next ex-dividend date N/A
Step 2: Sell Argenx shares (ARGX) when the price recovers.
Date of sale (estimated) N/A
Average price recovery N/A
Average return on cost N/A
The dividend capture strategy is based on historical Argenx data. Past performance is no guarantee of future results.

Information about Argenx

Full name argenx SE
Ticker ARGX
Sector Health Care
Industry Biotechnology
Market Capitalization 26.42B €
Number of Employees 843
Address Laarderhoogtweg 25, Amsterdam, 1101EB, Netherlands
Phone 31 10 703 8441
Description of the company

Argenx S.E., is a multinational company dedicated to the health industry, specifically to biotechnology, developing medical treatments and therapies to combat autoimmune diseases.

It was created in 2008 in Amsterdam, The Netherlands, its name is a derivation of the myth of the Argonauts, which refers to the power of teamwork, which in this case are engaged in seeking immunological solutions in order to help improve the lives of their patients, their products are also present in Belgium, United Kingdom, Japan, United States, Canada, Switzerland, Germany, Italy and France.

The main drug marketed is "efgartigimod", indicated for the treatment of diseases such as idiopathic inflammatory myopathy, immune thrombocytopenia, myasthenia gravis, bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus.

They also develop and market products such as ARGX-109, ARGX-112, ARGX-114, which is an antibody designed to control the mesenchymal-epithelial transition, ARGX-115, a specialized drug for the treatment of cancer, ARGX-116, ARGX-117 indicated for severe autoimmune diseases, ARGX-118 used in inflammation of the respiratory tract, ARGX-119, an antibody, among others.

Since its creation to date, it has made a series of strategic alliances with several companies to increase its processes and licenses, including Genmab, Staten Biotechnology, Pharma, AbbVie, LEO Pharma, Genor Biopharma, Zai Lab Limited, Université Catholique de Louvain, BioWa, Shire International GmbH, AgomAb Therapeutics, NYU Langone Health, Broteio, the University of Texas, among others.

Frequently asked questions about Argenx dividends

Argenx is listed on the Bolsa de Bruselas and is part of the BEL20.

Argenx has the Ticker or stock code ARGX.

Argenx belongs to the Health Care sector and the Biotechnology industry.

The CEO of Argenx in 2023 is Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc..

At this moment, the value of a Argenx share is 402.20€.

Argenx does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.

Argenx Forum

Check the latest comments and participate in the live chat on Argenx stocks (ARGX).
Notify of

Inline Feedbacks
View all comments